Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rapcabtagene autoleucel - Novartis

Next Previous
X
Search
Drug Profile

Rapcabtagene autoleucel - Novartis

Alternative Names: Anti-CD19 CAR-T cell therapy - Novartis; Anti-CD19 chimeric antigen receptor T cell therapy - Novartis; YTB-323; YTB323 Anti CD19 chimeric antigen receptor T cell therapy - Novartis

Latest Information Update: 12 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • Phase II Systemic scleroderma
  • Phase I/II Lupus nephritis; Systemic lupus erythematosus
  • No development reported Chronic lymphocytic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 Nov 2024 Novartis Pharmaceuticals plans a phase I/II trial for Myasthenia gravis (Treatment resistant) in January 2025 (IV) (NCT06704269)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, Second-line therapy or greater) in Australia (Parenteral, Infusion)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, Second-line therapy or greater) in Austria (Parenteral, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top